You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEPIBATIDINE
Accession NumberDB07720
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIM6K314F1XX
CAS numberNot Available
WeightAverage: 208.687
Monoisotopic: 208.076726133
Chemical FormulaC11H13ClN2
InChI KeyInChIKey=NLPRAJRHRHZCQQ-IVZWLZJFSA-N
InChI
InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2/t8-,9+,10+/m0/s1
IUPAC Name
(1R,2R,4S)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane
SMILES
[H][C@@]12CC[C@@]([H])(N1)[C@]([H])(C2)C1=CC=C(Cl)N=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as epibatidine analogues. These are compounds containing an epibatidine moiety, with a structure characterized by a 2-chloropyridine moiety connected to an 7-azabicyclo[2.2.1]heptane in exo position.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassEpibatidine analogues
Sub ClassNot Available
Direct ParentEpibatidine analogues
Alternative Parents
Substituents
  • Epibatidine-skeleton
  • Pyrrolidinylpyridine
  • Aralkylamine
  • Pyridine
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Pyrrolidine
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9767
Caco-2 permeable-0.5099
P-glycoprotein substrateNon-substrate0.6541
P-glycoprotein inhibitor INon-inhibitor0.7432
P-glycoprotein inhibitor IINon-inhibitor0.8989
Renal organic cation transporterNon-inhibitor0.5127
CYP450 2C9 substrateNon-substrate0.8639
CYP450 2D6 substrateNon-substrate0.7657
CYP450 3A4 substrateNon-substrate0.6359
CYP450 1A2 substrateNon-inhibitor0.7682
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6843
Ames testNon AMES toxic0.6607
CarcinogenicityNon-carcinogens0.9402
BiodegradationNot ready biodegradable0.992
Rat acute toxicity2.6084 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8853
hERG inhibition (predictor II)Non-inhibitor0.508
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.467 mg/mLALOGPS
logP1.98ALOGPS
logP1.84ChemAxon
logS-2.6ALOGPS
pKa (Strongest Basic)10.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.92 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity57.39 m3·mol-1ChemAxon
Polarizability22.07 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Csaba Sz antay, Zsuzsanna B. Kardos, Istv an Moldvai, Eszter T. Major, Csaba Sz antay, Jr., Attila M andi, G abor Blask o, Gyula Simig, Gy orgyi Lax, S andor Drabant, Tamas Sz all asi, M arton Fekete, G abor Gigler, “Process for the preparation of epibatidine.” U.S. Patent US5545741, issued March, 1994.

US5545741
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with EPIBATIDINE.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with EPIBATIDINE.
AlprenololThe risk or severity of adverse effects can be increased when Alprenolol is combined with EPIBATIDINE.
AmbenoniumThe risk or severity of adverse effects can be increased when Ambenonium is combined with EPIBATIDINE.
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with EPIBATIDINE.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with EPIBATIDINE.
BefunololThe risk or severity of adverse effects can be increased when Befunolol is combined with EPIBATIDINE.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with EPIBATIDINE.
BevantololThe risk or severity of adverse effects can be increased when Bevantolol is combined with EPIBATIDINE.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with EPIBATIDINE.
BopindololThe risk or severity of adverse effects can be increased when Bopindolol is combined with EPIBATIDINE.
BufuralolThe risk or severity of adverse effects can be increased when Bufuralol is combined with EPIBATIDINE.
BupranololThe risk or severity of adverse effects can be increased when Bupranolol is combined with EPIBATIDINE.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with EPIBATIDINE.
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with EPIBATIDINE.
CeliprololThe risk or severity of adverse effects can be increased when Celiprolol is combined with EPIBATIDINE.
CimetropiumEPIBATIDINE may decrease the anticholinergic activities of Cimetropium.
CoumaphosThe risk or severity of adverse effects can be increased when Coumaphos is combined with EPIBATIDINE.
DecamethoniumThe risk or severity of adverse effects can be increased when Decamethonium is combined with EPIBATIDINE.
DemecariumThe risk or severity of adverse effects can be increased when Demecarium is combined with EPIBATIDINE.
DichlorvosThe risk or severity of adverse effects can be increased when Dichlorvos is combined with EPIBATIDINE.
DonepezilThe risk or severity of adverse effects can be increased when Donepezil is combined with EPIBATIDINE.
EchothiophateThe risk or severity of adverse effects can be increased when Echothiophate is combined with EPIBATIDINE.
EdrophoniumThe risk or severity of adverse effects can be increased when Edrophonium is combined with EPIBATIDINE.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with EPIBATIDINE.
FenthionThe risk or severity of adverse effects can be increased when Fenthion is combined with EPIBATIDINE.
GalantamineThe risk or severity of adverse effects can be increased when Galantamine is combined with EPIBATIDINE.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with EPIBATIDINE.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Ginkgo biloba is combined with EPIBATIDINE.
Huperzine AThe risk or severity of adverse effects can be increased when Huperzine A is combined with EPIBATIDINE.
IndenololThe risk or severity of adverse effects can be increased when Indenolol is combined with EPIBATIDINE.
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with EPIBATIDINE.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with EPIBATIDINE.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with EPIBATIDINE.
MalathionThe risk or severity of adverse effects can be increased when Malathion is combined with EPIBATIDINE.
MefloquineThe risk or severity of adverse effects can be increased when Mefloquine is combined with EPIBATIDINE.
MemantineThe risk or severity of adverse effects can be increased when Memantine is combined with EPIBATIDINE.
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with EPIBATIDINE.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with EPIBATIDINE.
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with EPIBATIDINE.
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with EPIBATIDINE.
NeostigmineThe risk or severity of adverse effects can be increased when Neostigmine is combined with EPIBATIDINE.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with EPIBATIDINE.
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with EPIBATIDINE.
PhysostigmineThe risk or severity of adverse effects can be increased when Physostigmine is combined with EPIBATIDINE.
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with EPIBATIDINE.
PractololThe risk or severity of adverse effects can be increased when Practolol is combined with EPIBATIDINE.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with EPIBATIDINE.
PyridostigmineThe risk or severity of adverse effects can be increased when Pyridostigmine is combined with EPIBATIDINE.
RivastigmineThe risk or severity of adverse effects can be increased when Rivastigmine is combined with EPIBATIDINE.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with EPIBATIDINE.
TacrineThe risk or severity of adverse effects can be increased when Tacrine is combined with EPIBATIDINE.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with EPIBATIDINE.
TrichlorfonThe risk or severity of adverse effects can be increased when Trichlorfon is combined with EPIBATIDINE.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with EPIBATIDINE.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Extracellular ligand-gated ion channel activity
Specific Function:
Not Available
Gene Name:
CHRFAM7A
Uniprot ID:
Q494W8
Molecular Weight:
46217.335 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on September 15, 2010 15:25 / Updated on August 17, 2016 12:24